Abbott India Partners With Novo Nordisk to Launch Extensor® for Diabetes Care
Abbott India has announced a strategic partnership with Novo Nordisk India to launch Extensor® (semaglutide injection) for type 2 diabetes management. This collaboration combines Novo Nordisk's GLP-1 expertise with Abbott's distribution network to expand access to advanced diabetes therapy across India, targeting the country's growing diabetes burden of over 100 million people.
*this image is generated using AI for illustrative purposes only.
Abbott India has announced a strategic partnership with Novo Nordisk India to commercialize Extensor® (semaglutide injection) for people living with type 2 diabetes. This collaboration brings together Novo Nordisk's global GLP-1 leadership and Abbott's strong distribution network to expand access to evidence-based diabetes therapy across India.
Partnership Overview
Under this strategic agreement, Abbott will commercialize Novo Nordisk's semaglutide under the brand name Extensor®, which is a second brand of Ozempic®, the world's most prescribed GLP-1 RA (receptor agonist) molecule. The partnership leverages Abbott's established market presence in India with Novo Nordisk's specialized expertise in diabetes care solutions.
| Partnership Details: | Information |
|---|---|
| Partners: | Abbott India & Novo Nordisk India |
| Product: | Extensor® (semaglutide injection) |
| Original Brand: | Ozempic® |
| Target Condition: | Type 2 diabetes |
| Availability: | Expected soon in India |
Product Benefits and Clinical Evidence
Extensor® is approved as an adjunct to diet and exercise for adults with type 2 diabetes. The medication offers powerful HbA1c reduction, compelling weight-loss benefits, and proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes. Semaglutide has demonstrated safety and efficacy through 44+ robust clinical trials and 10+ real-world studies, with more than 49 million patient years of use across all semaglutide products globally.
| Clinical Benefits: | Details |
|---|---|
| HbA1c Reduction: | Powerful glucose control |
| Weight Management: | Compelling weight-loss benefits |
| Cardiovascular: | Proven risk reduction |
| Kidney Protection: | Reduced kidney event risk |
| Clinical Trials: | 44+ robust studies |
Market Context and Need
India faces one of the world's fastest-growing diabetes burdens, with more than 100 million individuals currently living with diabetes. This number is projected to surge to more than 150 million by 2050—a 50% increase driven by rapid urbanization, aging populations, increasing obesity and lifestyle changes. The country faces a significant care gap, with 43% of individuals with diabetes remaining undiagnosed, limiting opportunities for early intervention.
Leadership Statements
Kartik Rajendran, Managing Director of Abbott India Limited, emphasized that addressing India's diabetes challenge requires continuous innovation and strong partnerships. He noted that Extensor® builds on Abbott's longstanding focus on holistic diabetes management, from medicines to diagnostics and continuous glucose monitoring to diabetes-specific nutrition.
Vikrant Shrotriya, Managing Director of Novo Nordisk India, highlighted that semaglutide represents one of the most significant scientific advancements in diabetes care in recent decades, offering meaningful improvements in metabolic, renal and cardiovascular health. The partnership with Abbott will help make this innovative molecule accessible to a greater number of people living with type 2 diabetes in India.
Historical Stock Returns for Abbott
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.66% | +0.51% | -4.50% | -16.79% | -11.46% | +84.37% |
